Maria M. Plazzi
Rome, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Effectiveness of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide from Rilpivirine or Other Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Based Antiretroviral Therapy in Virologically Suppressed People with HIV: A Retrospective Analysis (DRIVE-SWITCH Study).
Journal: Infectious diseases and therapy
Published: December 22, 2025
Determinants of non-compliance with additional booster doses of the SARS-CoV-2 vaccine in people living with HIV (PWH): An observational study based on a behavioral and epidemiological survey in Rome (Italy).
Journal: Human vaccines & immunotherapeutics
Published: November 06, 2025
Switching to bictegravir/emtricitabine/tenofovir alafenamide from efavirenz/emtricitabine/tenofovir disoproxil in virologically suppressed people with HIV: findings from a non-randomized clinical trial (EBONY study).
Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Published: March 11, 2025
Effectiveness and Tolerability of DOR/3TC/TDF in Experienced People with HIV Switching from RPV/FTC/TDF: A Retrospective, Single Center Cohort Study.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: October 29, 2024
Impact of switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate to bictegravir/emtricitabine/tenofovir alafenamide on psychiatric symptoms and neurocognition.
Journal: AIDS (London, England)
Published: July 02, 2024
Rapid ART initiation with bictegravir/emtricitabine/tenofovir alafenamide in individuals presenting with advanced HIV disease (Rainbow study).
Journal: International journal of antimicrobial agents
Published: July 16, 2023
Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study).
Journal: EClinicalMedicine
Published: November 29, 2022
Declining Prevalence of Human Immunodeficiency Virus (HIV)-Associated Neurocognitive Disorders in Recent Years and Associated Factors in a Large Cohort of Antiretroviral Therapy-Treated Individuals With HIV.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: June 04, 2022
Virological and Immunological Outcomes of an Intensified Four-Drug versus a Standard Three-Drug Antiretroviral Regimen, Both Integrase Strand Transfer Inhibitor-Based, in Primary HIV Infection.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: March 02, 2022
Safety and immune response kinetics of GRAd-COV2 vaccine: phase 1 clinical trial results.
Journal: NPJ vaccines
Published: February 18, 2022
Characteristics and Outcomes of COVID-19-Related Hospitalization among PLWH.
Journal: Journal of clinical medicine
Published: February 12, 2022
Safety and serum distribution of anti-SARS-CoV-2 monoclonal antibody MAD0004J08 after intramuscular injection.
Journal: Nature communications
Published: January 27, 2022
Last Updated: 09/26/2026